ImmunoPrecise Antibodies Net Income

The latest net income for IPA is $-12M as of January 2026. That compares with $-46M in the prior-year period — up 73.5% year over year. That is below the Healthcare sector average of $17B. Investors often review this figure alongside ImmunoPrecise Antibodies's historical trend and sector peers before judging valuation or financial health.

Over the past year, IPA's net income moved from $-46M to $-12M — a 73.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ImmunoPrecise Antibodies's operating scale or balance-sheet position.

Against Healthcare companies, IPA currently prints $-12M for net income, while the sector average sits near $17B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at ImmunoPrecise Antibodies's growth, margins, and balance sheet.

A net income figure of $-12M for IPA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $17B. Explore the charts below for those layers of context.

After noting IPA's net income ($-12M), review year-over-year change from $-46M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.